The MiRNA Profile in Non-Hodgkin's Lymphoma Patients with Secondary Myelodysplasia

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2020 Oct 22

PMID 33086588

Citations 4

Authors

Yuliya Andreevna Veryaskina

Sergei Evgenievich Titov

Igor Borisovich Kovynev

Tatiana Ivanovna Pospelova

Igor Fyodorovich Zhimulev

Affiliations

Soon will be listed here.

Abstract

Myelodysplastic syndromes are a group of clonal diseases of hematopoietic stem cells and are characterized by multilineage dysplasia, ineffective hematopoiesis, peripheral blood cytopenias, genetic instability and a risk of transformation to acute myeloid leukemia. Some patients with non-Hodgkin lymphomas (NHLs) may have developed secondary myelodysplasia before therapy. Bone marrow (BM) hematopoiesis is regulated by a spectrum of epigenetic factors, among which microRNAs (miRNAs) are special. The aim of this work is to profile miRNA expression in BM cells in untreated NHL patients with secondary myelodysplasia. A comparative analysis of miRNA expression levels between the NHL and non-cancer blood disorders samples revealed that let-7a-5p was upregulated, and miR-26a-5p, miR-199b-5p, miR-145-5p and miR-150-5p were downregulated in NHL with myelodysplasia ( < 0.05). We for the first time developed a profile of miRNA expression in BM samples in untreated NHL patients with secondary myelodysplasia. It can be assumed that the differential diagnosis for blood cancers and secondary BM conditions based on miRNA expression profiles will improve the accuracy and relevance of the early diagnosis of cancerous and precancerous lesions in BM.

Citing Articles

Multiple Myeloma: Genetic and Epigenetic Biomarkers with Clinical Potential.

Veryaskina Y, Titov S, Skvortsova N, Kovynev I, Antonenko O, Demakov S Int J Mol Sci. 2025; 25(24.

PMID: 39769169 PMC: 11679576. DOI: 10.3390/ijms252413404.

The Profile of MicroRNA Expression in Bone Marrow in Non-Hodgkin's Lymphomas.

Veryaskina Y, Titov S, Kovynev I, Pospelova T, Zhimulev I Diagnostics (Basel). 2022; 12(3).

PMID: 35328182 PMC: 8947746. DOI: 10.3390/diagnostics12030629.

Selection of reference genes for quantitative analysis of microRNA expression in three different types of cancer.

Veryaskina Y, Titov S, Ivanov M, Ruzankin P, Tarasenko A, Shevchenko S PLoS One. 2022; 17(2):e0254304.

PMID: 35176014 PMC: 8853544. DOI: 10.1371/journal.pone.0254304.

MicroRNAs in the Myelodysplastic Syndrome.

Veryaskina Y, Titov S, Kovynev I, Fedorova S, Pospelova T, Zhimulev I Acta Naturae. 2021; 13(2):4-15.

PMID: 34377552 PMC: 8327150. DOI: 10.32607/actanaturae.11209.

Profiling 25 Bone Marrow microRNAs in Acute Leukemias and Secondary Nonleukemic Hematopoietic Conditions.

Kovynev I, Titov S, Ruzankin P, Agakishiev M, Veryaskina Y, Nedelko V Biomedicines. 2020; 8(12).

PMID: 33327422 PMC: 7764834. DOI: 10.3390/biomedicines8120607.

References

Jiang W, Min J, Sui X, Qian Y, Liu Y, Liu Z . MicroRNA-26a-5p and microRNA-23b-3p up-regulate peroxiredoxin III in acute myeloid leukemia. Leuk Lymphoma. 2014; 56(2):460-71. PMC: 4364273. DOI: 10.3109/10428194.2014.924115. View

Lam J, van den Bosch M, Wegrzyn J, Parker J, Ibrahim R, Slowski K . miR-143/145 differentially regulate hematopoietic stem and progenitor activity through suppression of canonical TGFβ signaling. Nat Commun. 2018; 9(1):2418. PMC: 6010451. DOI: 10.1038/s41467-018-04831-3. View

Choi Y, Hur E, Moon J, Goo B, Choi D, Lee J . Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome. Korean J Intern Med. 2017; 34(2):390-400. PMC: 6406090. DOI: 10.3904/kjim.2016.239. View

Fang Z, Wang S, Zhao J, Lin Z, Chen L, Su R . miR-150 exerts antileukemia activity in vitro and in vivo through regulating genes in multiple pathways. Cell Death Dis. 2016; 7(9):e2371. PMC: 5059860. DOI: 10.1038/cddis.2016.256. View

Sokol L, Caceres G, Volinia S, Alder H, Nuovo G, Liu C . Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol. 2011; 153(1):24-32. PMC: 4294220. DOI: 10.1111/j.1365-2141.2011.08581.x. View

Tanaka T, Bejar R . MDS overlap disorders and diagnostic boundaries. Blood. 2019; 133(10):1086-1095. DOI: 10.1182/blood-2018-10-844670. View

Zuo Z, Calin G, de Paula H, Medeiros L, Fernandez M, Shimizu M . Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood. 2011; 118(2):413-5. PMC: 3293748. DOI: 10.1182/blood-2011-01-330704. View

Mohammad A . Myelodysplastic syndrome from theoretical review to clinical application view. Oncol Rev. 2019; 12(2):397. PMC: 6291758. DOI: 10.4081/oncol.2018.397. View

Yasmeen T, Ali J, Khan K, Siddiqui N . Frequency and causes of anemia in Lymphoma patients. Pak J Med Sci. 2019; 35(1):61-65. PMC: 6408630. DOI: 10.12669/pjms.35.1.91. View

10.

Dozzo M, Zaja F, Volpetti S, Chiozzotto M, Puglisi S, Mazzucco M . Two cases of concomitant diffuse large B-cell lymphoma and myelodysplastic syndrome. Am J Hematol. 2014; 89(10):1011-3. DOI: 10.1002/ajh.23783. View

11.

Fabregat I, Fernando J, Mainez J, Sancho P . TGF-beta signaling in cancer treatment. Curr Pharm Des. 2013; 20(17):2934-47. DOI: 10.2174/13816128113199990591. View

12.

Luo S, Liu Y, Liang G, Zhao M, Wu H, Liang Y . The role of microRNA-1246 in the regulation of B cell activation and the pathogenesis of systemic lupus erythematosus. Clin Epigenetics. 2015; 7:24. PMC: 4364674. DOI: 10.1186/s13148-015-0063-7. View

13.

Starczynowski D, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A . Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med. 2009; 16(1):49-58. DOI: 10.1038/nm.2054. View

14.

Vlachos I, Zagganas K, Paraskevopoulou M, Georgakilas G, Karagkouni D, Vergoulis T . DIANA-miRPath v3.0: deciphering microRNA function with experimental support. Nucleic Acids Res. 2015; 43(W1):W460-6. PMC: 4489228. DOI: 10.1093/nar/gkv403. View

15.

Getaneh Z, Asrie F, Melku M . MicroRNA profiles in B-cell non-Hodgkin lymphoma. EJIFCC. 2019; 30(2):195-214. PMC: 6599190. View

16.

Guo K, Zheng S, Xu Y, Xu A, Chen B, Wen Y . Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. Tumour Biol. 2016; 37(9):12843-12854. DOI: 10.1007/s13277-016-5158-z. View

17.

Polivka Jr J, Janku F . Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2013; 142(2):164-75. DOI: 10.1016/j.pharmthera.2013.12.004. View

18.

Kozomara A, Birgaoanu M, Griffiths-Jones S . miRBase: from microRNA sequences to function. Nucleic Acids Res. 2018; 47(D1):D155-D162. PMC: 6323917. DOI: 10.1093/nar/gky1141. View

19.

Kotaki R, Koyama-Nasu R, Yamakawa N, Kotani A . miRNAs in Normal and Malignant Hematopoiesis. Int J Mol Sci. 2017; 18(7). PMC: 5535985. DOI: 10.3390/ijms18071495. View

20.

Hrustincova A, Krejcik Z, Kundrat D, Szikszai K, Belickova M, Pecherkova P . Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome. Cells. 2020; 9(4). PMC: 7226126. DOI: 10.3390/cells9040794. View